Welcome to our dedicated page for Purple Biotech Ltd. American Depositary Shares news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech Ltd. American Depositary Shares stock.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company based in Rehovot, Israel, dedicated to developing innovative cancer therapies that harness the tumor microenvironment to overcome immune evasion and drug resistance. The company's oncology pipeline includes two main drug candidates, CM24 and NT219, along with a pioneering platform of conditionally-activated tri-specific antibodies.
CM24 is a multi-functional immune checkpoint inhibitor undergoing Phase 2 clinical trials for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study, in collaboration with Bristol Myers Squibb, is evaluating CM24 combined with nivolumab and chemotherapy as a second-line treatment. The primary endpoint is overall survival, with interim results expected by mid-2024 and topline data by the end of the same year.
NT219 is a small molecule dual inhibitor targeting IRS1/2 and STAT3. It has shown promising results in a Phase 1/2 dose escalation study for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). A Phase 2 study is planned for NT219 in combination with cetuximab, set to begin in the first half of 2024.
Additionally, Purple Biotech’s tri-specific antibody platform aims to conditionally activate T cells and natural killer (NK) cells within the tumor microenvironment. The platform's lead candidate, IM1240, targets 5T4, a tumor-associated antigen, and is designed to induce a localized immune response while minimizing off-tumor side effects.
Recent financial reports indicate that Purple Biotech has a solid cash runway into the first half of 2025, thanks to strategic funding and partnerships. The company’s research and development expenses have seen a slight increase due to ongoing clinical trials, while selling, general, and administrative expenses have decreased.
For more detailed information and the latest updates, visit Purple Biotech’s website.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) recently inaugurated its Scientific Advisory Board (SAB), comprised of three experts from oncology and cancer research. This initiative aims to enhance the company's strategic direction in developing innovative cancer therapies targeting tumor immune evasion and drug resistance. The SAB includes distinguished members: Eyal Gottlieb, PhD, from MD Anderson; Steven Maron, MD, from Memorial Sloan Kettering; and Sunil Sharma, MD, MBA, from Translational Genomics. The board will assist management by providing scientific guidance on clinical trials and R&D activities, which is expected to aid in the advancement of the company’s oncology pipeline, including therapies like NT219 and CM24.
Purple Biotech (NASDAQ/TASE: PPBT) has unveiled promising preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2023, held on April 18, 2023. The results highlight the effectiveness of NT219, a novel small molecule dual inhibitor targeting IRS1/2 and STAT3, in enhancing immune responses in the tumor microenvironment (TME).
Key findings include:
- NT219 significantly increased PDL1 expression in resistant melanoma cells and enhanced anti-PD1 therapy effectiveness.
- In combination with anti-PD1 or anti-CTLA4, NT219 drove significant increases in activated CD8 cytotoxic T and NK cells while decreasing immunosuppressive cell populations.
- NT219 showed lasting effects on IRS1 and STAT3 phosphorylation, linked to tumor drug resistance.
The results indicate NT219 could convert resistant tumors into responders for immune checkpoint blockade therapies.
Purple Biotech (NASDAQ/TASE: PPBT) announced the participation of Dr. Amir Horowitz at Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference on April 20, 2023. He will present on the newly acquired Tri-specific antibody as part of the panel titled New & better Approaches for Oncology Targets. The presentation will take place from 2:00-2:45 PM ET, and a live webcast will be accessible to registered attendees.
Purple Biotech is a clinical-stage company focused on therapies that combat tumor immune evasion and drug resistance. Its oncology pipeline includes NT219, CM24, and IM1240, addressing various solid tumors. The ongoing studies involve NT219, which targets IRS1/2 and STAT3, and CM24, a monoclonal antibody in collaboration with Bristol Myers Squibb.
FAQ
What is the current stock price of Purple Biotech Ltd. American Depositary Shares (PPBT)?
What is the market cap of Purple Biotech Ltd. American Depositary Shares (PPBT)?
What is Purple Biotech Ltd. focused on?
What are the main drug candidates in Purple Biotech's pipeline?
What is CM24?
What is NT219?
What is unique about Purple Biotech’s tri-specific antibody platform?
What recent milestones has Purple Biotech achieved?
What are Purple Biotech's financial highlights?
Who are Purple Biotech's key partners?
Where is Purple Biotech headquartered?
Where can I find more information about Purple Biotech?
